Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
NCT00894504
Completed
In this Phase II trial, the investigators will evaluate the combination of gemcitabine, carboplatin, and panitumumab in the treatment of patients with metastatic triple-negative breast cancer. In addition, to assess the efficacy of this combination, tumor tissue will be examined for the presence of various markers, including K-ras and PI3K-activating mutations, EGFR, PTEN, and p53. Correlation of tumor response with marker expression may define a patient subset that is particularly responsive to... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2015
Locations: Texas Health Physician Group, Dallas, Texas
Conditions: Metastatic Breast Cancer
Register for Updates
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
NCT00316186
Completed
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2015
Locations: GSK Investigational Site, Amarillo, Texas
Conditions: Lung Cancer, Small Cell
Register for Updates
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
NCT00984464
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2015
Locations: Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas
Conditions: Metastatic Melanoma
Register for Updates
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
NCT00254891
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2015
Locations: Pfizer Investigational Site, Arlington, Texas +7 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
NCT00529503
Terminated
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/06/2015
Locations: Baylor Sammons Cancer Center, Dallas, Texas +1 locations
Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Register for Updates
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
NCT00090610
Completed
The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/05/2015
Locations: Southwest Regional Cancer Center, Austin, Texas
Conditions: Ovarian Cancer
Register for Updates
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
NCT00735696
Completed
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2014
Locations: ImClone Investigational Site, San Antonio, Texas
Conditions: Non Small Cell Lung Cancer
Register for Updates
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
NCT00003313
Completed
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: Harrington Cancer Center, Amarillo, Texas +7 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Register for Updates
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
NCT00753038
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus in combination with Paclitaxel and Carboplatin is effective and safe in the treatment of squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas
Conditions: Carcinoma, Squamous Cell of the Head and Neck
Register for Updates
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
NCT01166542
Completed
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: Texas Oncology- Sammons Cancer Center, Dallas, Texas +2 locations
Conditions: Carcinoma, Squamous Cell of the Head and Neck
Register for Updates
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
NCT00300885
Terminated
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2014
Locations: Not set, Trophy Club, Texas
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
NCT00111007
Completed
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2014
Locations: Not set, Houston, Texas
Conditions: Melanoma
Register for Updates